The infant exposed to opioids in utero frequently presents a challenge to the neonatal care
provider in the assessment and treatment of symptoms of Neonatal Abstinence Syndrome …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …

The management of the infant exposed to drugs in utero poses significant challenges.
Symptoms and signs of neonatal abstinence syndrome (NAS) are non-specific but most …

Background Neonatal abstinence syndrome (NAS) includes an array of symptoms impacting
opioid-exposed newborns (OEN) owing to postnatal withdrawal from in utero substance …

Neonatal Abstinence Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Neonates who have had in utero exposures from maternal substance abuse can experience
central nervous system effects of the drugs, including drug toxicity and withdrawal. Neonatal …

Neonatal withdrawal symptoms have been noted following prenatal exposure to several
drugs. Examples include opioids, 1, 2 benzodiazepines, 3, 4 mood-stabilizing medications …

Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

Aims: To determine the monitoring and treatment of neonatal abstinence syndrome (NAS) in
neonatal intensive care units (NICUs) following opiate or polydrug exposure in utero …

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …